Skip to content

Botulinum Toxin Injection to Treat Diffuse Esophageal Spasm

Prospective Randomised Double-blind Sham Study on the Use of Botox for the Treatment of Diffuse Esophageal Spasm

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01432782
Acronym
Botox
Enrollment
30
Registered
2011-09-13
Start date
2010-02-28
Completion date
2013-12-31
Last updated
2011-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Spasm, Diffuse

Keywords

Weight loss, Dysphagia, Esophageal hypermotility, Chest Pain

Brief summary

This study evaluates the effect of botulinum toxin 100 U or saline, injected endoscopically in the distal esophagus, on symptoms and manometry pattern in patients with diffuse esophageal spasm.

Detailed description

Patients are selected on the basis of a clinical diagnosis of diffuse esophageal spasm, based on endoscopy and manometry. This is a sham-controlled cross-over study of injection of botulinum toxin or saline, in randomized order, in the distal esophagus. All patients have undergone esophageal manometry which shows diffuse esophageal spasm, and a 24h pH monitoring/manometry to quantify acid reflux. All drugs prescribed to affect esophageal motility (nitrates, calcium antagonists) are stopped during the study. After randomisation, the patient will undergo standard esophageal manometry to assess baseline esophageal motility. On the same day the patient will be asked to fill out a set of symptom questionnaires including a dysphagia questionnaire. At endoscopy, the active treatment group receives 8 x 12.5 units, each in 0.5 ml, of botulinum toxin A which will be injected in the four quadrants of the esophagus at 2 and 5 cm above the lower esophageal sphincter. In the Sham group 8 \* 0.5 ml of physiologic serum will be injected. The randomisation will be performed at the endoscopy unit by a nurse otherwise not involved in the protocol. After 1 month a stationary manometry and a new esophageal pH/manometry monitoring will be performed, followed by a second endoscopy with injection of saline or botulinum toxin in a cross-over mode. At the time of the second endoscopy each patient will fill out a dysphagia questionnaire. One month later, the dysphagia questionnaire is repeated. Subsequently, follow-up will occur at the outpatient clinic after 6 and 12 months, with follow-up dysphagia questionnaires but no additional manometries or endoscopies, unless the clinical status deteriorates.

Interventions

DRUGPlacebo

Saline 4 ml

DRUGBotulinum Toxin Type A

per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Spastic motor disorder in the upper GI tract

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Dysphagia severity scoreOne month after treatmentthe primary outcome variable is the symptom severity score in patients with diffuse esophageal spasm.

Secondary

MeasureTime frameDescription
Manometry patternOne month after treatmentPattern of contractions on stationary esophageal manometry

Countries

Belgium

Contacts

Primary ContactJan Tack, M.D., Ph.D.
jan.tack@med.kuleuven.be+321634425

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026